钠葡萄糖共转运蛋白2抑制剂治疗射血分数保留型心衰的最新进展

Recent progress of sodium glucose cotransporter 2 inhibitors in treatment of heart failure with preserved ejection fraction

心衰是各种心脏疾病的严重表现或晚期阶段,死亡率和再住院率居高不下,成为正在危害人类健康的重要疾病之一。射血分数保留的心衰(HFpEF)占比达心衰患者一半以上,但目前尚无确切的可以降低HFpEF发病率和死亡率的治疗策略。近年来,新型降糖药物钠葡萄糖共转运蛋白2抑制剂(SGLT-2i)带来的心血管益处得到了广泛的关注,HFpEF患者是否可以从SGLT-2i中获益备受关注,现就这一问题作一综述。

Heart failure is a serious manifestation or late stage of various heart diseases with high mortality and re-hospitalization rate and is becoming one of the important diseases endangering human health.Heart failure with preserved ejection fraction(HFpEF)accounts for more than half of the patients with HF,but currently there is no definitive treatment strategy to reduce the morbidity and mortality of HFpEF.In recent years,the cardiovascular benefits of SGLT-2 i,a novel hypoglycemic drug,have been widely concerned and whether HFpEF patients can benefit from SGLT-2 I has attracted much attention.This paper will review this issue.